Application
Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using I kappa B- beta (Phospho-Ser23) Antibody (left) or the same antibody preincubated with blocking peptide (right).| Product Name | IKB beta (phospho Ser23) antibody |
|---|---|
| Antibody Type | Primary Antibodies |
| Product description | Rabbit Polyclonal antibody to IKB beta (phospho Ser23)Inhibits NF-kappa-B by complexing with and trapping it in the cytoplasm. However, the unphosphorylated form resynthesized after cell stimulation is able to bind NF-kappa-B allowing its transport to the nucleus and protecting it to further IKBA-dependent inactivation. Association with inhibitor kappa B-interacting NKIRAS1 and NKIRAS2 prevent its phosphorylation rendering it more resistant to degradation, explaining its slower degradation. |
| Immunogen | Peptide sequence around phosphorylation site of serine 23 (L-G-S(p)-L-G) derived from Human I kappa B- beta . |
| Modification | p-Ser23 |
| Clonality | Polyclonal |
|---|---|
| Host Species | Rabbit |
| Tested Applications | IHC-P |
| Suggested starting dilutions are as follows. IHC-P: 1:50~1:100. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user.: |
|
| Species Reactivity | HumanMouseRat |
| Concentration | 1mg/ml (Please refer to the vial label for the specific concentration) |
| Purification | Affinity purified |
| Gene Synonyms | IKBB TRIP9 NFKBIB TR-interacting protein 9 TRIP-9 ikappaBbeta I-kappa-B-beta ikB-B NF-kappa-BIB NF-kappa-B inhibitor beta ikB-beta thyroid receptor-interacting protein 9 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibit |
|---|---|
| Target | I kappa B beta (Phospho Ser23) |
| Molecular Weight(MW) | 48 (note) |
Application
Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using I kappa B- beta (Phospho-Ser23) Antibody (left) or the same antibody preincubated with blocking peptide (right).| Application Notes | Suggested starting dilutions are as follows. IHC-P: 1:50~1:100. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user.: |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | Keep as concentrated solution. Aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
